Table 3.
Sensitivity analysis after excluding participants on vitamin D
| FGF23 (RU/mL) | Before sodium bicarbonatea | After sodium bicarbonate | p-value |
|---|---|---|---|
| Taking vitamin Db | |||
| Yes (n = 9) | 217.0 (146.4–353.2)* | 327.4 (231.7–410.9) | 0.31 |
| No (n = 20) | 121.2 (85.1–162.4)* | 147.4 (107.0–196.5) | 0.08 |
| Taking paricalcitol | |||
| Yes (n = 3) | 353.2 (98.9–824.9)** | 399.1 (327.4–410.9) | 0.59 |
| No (n = 17) | 146.4 (116.5–217.0)** | 185.7 (129.9–238.4) | 0.009 |
| Increased paricalcitol dose | |||
| Yes (n = 1)c | 98.8 | 399.1 | N/A |
| No (n = 19) | 155.5 (116.5–286.5) | 186.4 (129.9–306.4) | 0.08 |
| Participant #16d | |||
| Yes (n = 1) | 824.9 | 410.9 | N/A |
| No (n = 19) | 146.4 (98.8–248.3) | 186.4 (129.9–306.4) | 0.01 |
FGF23 was expressed in median (interquartile range)
Abbreviation: N/A not applicable
* p-value comparing FGF23 between those taking vitamin D and those not taking vitamin D = 0.06
** p-value comparing FGF23 between those taking paricalcitol and those not taking paricalcitol = 0.02
aVariables for “before sodium bicarbonate” were the mean of values between the initial visit and after 2-week placebo
bVitamin D used included ergocalciferol, cholecalciferol and paricalcitol
cParticipant #3 had paricalcitol dose increased during the study
dParticipant #16 had very a high FGF23 level at baseline